Physician profile
Dan T Vu
NPI 1801425376
$20,258.34
in general payments reported to CMS, 2019-2025
12 companies · $7,389 in 2025
The $7,389 reported for 2025 was more than what 95% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $361 · 2023: $232 · 2024: $12K · 2025: $7,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,500 · Food and Beverage: $7,299 · Travel and Lodging: $5,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,500.00 |
| Food and Beverage | $7,298.80 |
| Travel and Lodging | $5,098.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,664.23 | 2024-2025 | Synchromedii, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Saluda Medical Americas, INC. | $2,975.58 | 2024-2025 | Evoke |
| Abbott Laboratories | $2,273.64 | 2024-2025 | Proclaim, Eterna |
| Nevro Corp. | $1,712.68 | 2022-2024 | Senza |
| Boston Scientific Corporation | $1,562.44 | 2024-2025 | General - Therapies, General - Pain Management, Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $1,286.86 | 2025 | Senza, Vyrsa V1 |
| Spr Therapeutics, INC | $341.28 | 2022-2025 | Sprint Pns System |
| Averitas Pharma INC. | $154.01 | 2025 | Qutenza |
| Nalu Medical, INC. | $118.28 | 2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $78.35 | 2025 | Ha Minuteman G3-R |
| Convatec INC. | $63.07 | 2025 | |
| Abbvie INC. | $27.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.